StockData
Fortress Biotech, Inc. logo

Fortress Biotech, Inc. (FBIO) company profile

FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/30
$1.82+0.11 (+6.43%)

Close on Nov 17, 2026Market cap $66.94MP/E –Yield –

About Fortress Biotech

Pharmaceutical Preparations, SIC 2834

Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical assets and product candidates. The company operates primarily through public partner companies and private subsidiaries, which collaborate with academic institutions and pharmaceutical partners. Its commercial offerings focus on branded dermatology therapies, including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, and other topical treatments for conditions such as rosacea, severe acne, and primary axillary hyperhidrosis. Fortress also advances a clinical and preclinical pipeline spanning oncology, viral infections, rare pediatric genetic disorders, and acute pain.

The company conducts its development and commercialization activities primarily in the United States, alongside global research partnerships, licensing arrangements, and multicenter clinical trials. Its commercial dermatology portfolio is marketed for sale within the United States. Fortress does not disclose specific facility counts or a corporate headquarters location in the provided text.

Summary of the business section of Fortress Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
Fortress Biotech, Inc.
Founded
2006
Headquarters
Bay Harbor Islands, FL
Address
1111 Kane Concourse, Suite 301 33154
Phone
(781) 652-4500
Employees
78, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, New York, NY

Stock & identifiers

Ticker
FBIO
Other tickers
FBIOP
Former tickers
CNDO until May 11, 2015
Exchange
Nasdaq
IPO date
Nov 17, 2011
Shares outstanding
37M, Aug 10, 2026
Public float
$43.74M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Oct 10, 2023
SEC CIK
1429260
CUSIP
34960Q307
ISIN
US34960Q3074
FIGI
BBG001J2MFH6
Share class FIGI
BBG001V0GB64
LEI
529900DZUWSYUURECK24
EIN
20-5157386

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael S. WeissExecutive Vice Chairman, Director2,276,562
Lindsay A. Rosenwald MdPRESIDENT, CEO & CHAIRMAN, Director6,954,507
David JinChief Financial Officer1,652,761
J. Jay LobellDirector192,397
Jimmie HarveyDirector146,704
Dov KleinDirector131,905
Kevin LorenzDirector101,675
Malcolm HoenleinDirector115,747
Lucy LuDirector61,273

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.89M$3.56M$1.55M––
FY2024$1.38M$807.50K$1.90M$5–
FY2023$1.12M-$1.90M$1.22M$8–
FY2022$1.27M-$8.74M$1.37M$26–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Lindsay A. Rosenwald, M.D.
Chairman, President and Chief Executive Officer
$62.67K$500.00K$2.20M$125.00K$2.89M+109%
David Jin
Chief Financial Officer and Head of Corporate Development
$427.88K$172.20K–$64.00K$664.08K-74%
Michael S. Weiss
Executive Vice Chairman, Strategic Development
$62.67K$500.00K$1.79M$90.00K$2.44M+98%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 78 full-time employees at Fortress and our subsidiaries and partner companies.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?